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Abstract 
When exposed to certain stimuli, phagocytes (including neutrophils, macrophages and 
eosinophils) undergo marked changes in the way they handle oxygen. Firstly, their rate of 
oxygen uptake increases greatly. This is accompanied by (i) the production of large amounts 
of superoxide and hydrogen peroxide and (ii) the metabolism of large quantities of glucose 
through the hexose monophosphate shunt. We now know that the oxygen used is not for 
respiration but for the production of powerful microbiocidal agents downstream of the initial 
production of superoxide. Concomitantly, glucose is oxidised through the hexose 
monophosphate shunt to re-generate the NADPH that has been consumed through the reduction 
of molecular oxygen to generate superoxide.  
This phagocyte respiratory burst is generated by an NADPH oxidase multi-protein complex 
that has a catalytic core consisting of membrane-bound gp91phox (CYBB) and p22phox 
(CYBA) sub-units and cytosolic components p47phox (NCF1), p67phox (NCF2) and p40phox 
(NCF4). Finally, another cytosolic component, the small G-protein Rac (Rac2 in neutrophils 
and Rac1 in macrophages) is also required for full activation. The importance of the complex 
in host defence is underlined by chronic granulomatous disease, a severe life-limiting 
immunodeficiency caused by mutations in the genes encoding the individual subunits. 
In this review, I will discuss the experimental evidence that underlies our knowledge of the 
respiratory burst, outlining how elegant biochemical analysis, coupled with study of patients 
deficient in the various subunits has helped elucidate the function of this essential part of innate 
immunity. I will also discuss some exciting recent studies that shed new light on how the 
abundance of the various components is controlled. Finally, I will explore the emerging role of 
reactive oxygen species such as superoxide and hydrogen peroxide in the pathogenesis of major 
human diseases including auto-inflammatory diseases. 
 
Discovery and Characterisation of the Phagocyte Respiratory Burst 
The first studies on the oxygen metabolism of phagocytes were carried out in the 1930s by 
Baldrige and Gerrard who showed that canine neutrophils undergo a marked increase in oxygen 
consumption while phagocytosing bacteria. No further investigation of this rather startling 
finding took place until the 1950s when the metabolic properties of neutrophils ingesting 
foreign material were re-examined. This work demonstrated several unusual features of oxygen 
consumption by leucocytes and ultimately led to delineation of the workings of the NADPH 
oxidase. Notably, the increased oxygen consumption first observed by Baldridge and Gerrard 
was accompanied by the catabolism of glucose through the hexose monophosphate shunt. 
Crucially, Sbarra and Karnovsky [1] showed that the increase in oxygen consumption was not 
blocked by inhibitors of mitochondrial oxidative respiration such as cyanide, anti-mycin C and 
dinitrophenol. Inhibitors of glycolysis did block the process, however. This begged the question 
of why this pronounced increase in oxygen uptake was necessary if it was not being used for 
for respiration. Elegant studies by Iyer, Quastel and colleagues in 1961 went some way to 
answering this question. They showed that, during phagocytosis, formate is effectively 
converted to 14CO2 and concluded that this catalytic oxidation of formate must be due to the 
production of substantial amounts of hydrogen peroxide. This was formally validated in 
subsequent work through direct measurement of H202 production [2, 3]. Thus, the augmented 
oxygen uptake seen during phagocytosis appeared to be necessary for the production of reactive 
oxygen species such as hydrogen peroxide but to what end? The hypothesis that the process 
was related to anti-microbial defence was explored by Klebanoff and colleagues in the late 
1960s who showed that the hydrogen peroxide produced could react with halide ions (such as 
chloride or iodide) to produce the anti-bacterial compound, hypochlorite (HOCL) [4, 5]. 
Crucially, this process was catalysed by myeloperoxidase, which was abundant in neutrophil 
granules. Thus a picture emerged where phagocytosis stimulated both MPO release and the 
production of hydrogen peroxide and then this in turn drove the generation of hypochlorite by 
the reaction below.  
 
Hypochlorite, the product of this reaction is itself a potent microbiocidal agent. It is also a 
precursor of the chloramines, which are oxidised halogens that also exhibit anti-microbial 
activity and are formed by the reaction of oxidised halogens with ammonia or amines [6]. A 
major advance in the field was then made by Curnutte and Babior ([7] and reviewed in [8]). 
They were also working on phagocytosis and had noted that while Klebanoff’s work had shown 
that reactive oxygen species could be microbiocidal via myeloperoxidase, an anomaly 
remained - namely that myeloperoxidase-deficient individuals were not particularly 
immunosuppressed except in the setting of other co-morbidities such as diabetes [9]. They 
reasoned that neutrophils may produce another anion via the phagocyte respiratory burst and 
that this was most likely to be superoxide. It was already established that mammalian cells 
could produce superoxide through processes such as the action of the enzyme xanthine oxidase 
or the oxidation of haemoglobin to methaemoglobin [10] [11]. Furthermore, eukaryotic cells 
protect themselves from the superoxide free radical by expressing superoxide dismutase (SOD) 
[12] but an intriguing observation was that many bacteria expressed superoxide dismutase too. 
Indeed, bacteria that were obligate anaerobes lacked super-oxide dismutase [13] while those 
that expressed it could survive in conditions where the oxygen tension was higher. Did bacteria 
express SOD in order to eliminate the superoxide generated by phagocytes? Curnutte and 
Babior were able to demonstrate that phagocytes certainly did make superoxide. Their seminal 
paper on the topic showed that human neutrophils reduced cytochrome c upon phagocytosis 
and that this could be inhibited by superoxide dismutase [7]. The only question that remained 
was whether these species were truly crucial to host defense.    
Selveraj and Sbarra had shown in 1966 that oxygen was necessary for killing of bacteria by 
phagocytes in vitro [14] but the in vivo importance of the process was conclusively 
demonstrated by work on chronic granulomatous disease (CGD). This syndrome had been 
described as a fatal X-linked disease of childhood characterised by recurrent infections 
including pneumonia, infectious dermatitis and recurrent abscesses. In a series of papers in 
1967-8, Holmes, Page and Good showed that the leucocytes of boys with CGD failed to show 
increments in respiration, direct oxidation of glucose, and hydrogen peroxide formation during 
particle uptake [15-17]. A slew of papers from that group and others confirmed and expanded 
upon these findings including demonstrations by Babior and Curnutte that phagocytes from 
several males with CGD were also unable to generate superoxide [18] 
The hunt was then on to determine the nature of the oxidase enzyme that must be missing in 
X-linked CGD. The main debate centred on whether NADH or NADPH was oxidised during 
the reduction of molecular oxygen. A putative NADPH oxidase had been described by Rossi 
[19] but Hohn and Lehrer’s work [20] is generally deemed to be the first definitive evidence 
that the enzyme responsible for generating superoxide is an NADPH oxidase. The evidence for 
this was based on the ability of such an oxidase to produce superoxide at a rate commensurate 
with that seen in human neutrophils and its absence in patients suffering from CGD.  
The exact identity of the oxidase enzyme came in 1978 with A.W. Segal’s demonstration that 
it was the newly described cytochrome b-245 enzyme (more commonly known now as 
gp91phox or Nox2) [21, 22] . It had been suspected for some time that a cytochrome would be 
involved in the process as these enzymes mediate electron transfer. In a series of papers, Segal 
and co-workers showed that an unusual b-type cytochrome localised to the plasma membrane 
of neutrophils and, most importantly, this cytochrome was absent in many patients with CGD. 
The cloning of the CYBB gene that encodes gp91phox bore out this hypothesis and is one of 
the first examples of positional cloning. From chromosome walking experiments , it was known 
that the gene localised to Xp21. Royer-Pokora [23] and colleagues isolated a cDNA that  was 
present in human leukaemic cells that expressed the NADPH oxidase and used subtractive 
hydbridisation to show that this cDNA was missing from a cell line with a patient with a large 
Xp21 deletion. Further validation was obtained by showing that this transcript was expressed 
in haematopoietic cells but was absent in 4 patients with CGD. This work was beautifully 
complimented by a follow-up paper in which antibodies were raised to a synthetic peptide 
derived from the complementary DNA sequence. By western blot, the antisera detected a 
neutrophil protein of about 90kDa that was absent in X-CGD patients. The antisera also 
detected gp91phox in complex with p22phox. [24] 
The enzyme has been extensively characterised in the last 30 years and we know now that it is 
localised to the plasma membrane and specific granules of neutrophils and can also localise to 
the membrane of the phagocytic vacuole upon ingestion of microbes. At this location, it forms 
a conduit for electrons to be pumped from NADPH in the cytosol to oxygen in the vacuole. 
The gp91phox molecule contains all the machinery necessary for this process to occur and the 
molecule comprises two domains specialised for this function. The C-terminal domain contains 
FAD and NADPH binding sites. The N-terminal domain contains 6 transmembrane spanning 
helices. Helices III and V contain highly conserved histidines (in fact, they are conserved across 
the whole family of NOX family enzymes). The function of these residues is to bind and anchor 
two prosthetic haem groups. Electrons are thus transferred via FAD through these two haem 
groups across the membrane from the cytosol to the  vacuole or extracellular space [25]. The 
importance of these histidines is supported by subsequent site directed mutagenesis studies 
[26].  
A further step forward in our understanding of the structure of the NADPH oxidase was 
provided in 1987 when Segal refined the technique for isolation of the gp91phox subunit by 
using more powerful protease inhibitors and a more rapid isolation technique. Isolation using 
this method showed that an additional 22 kDa protein co-purified with gp91phox. The two 
subunits (gp91phox and p22phox) were closely linked and remained associated with the heme 
of the cytochrome through both affinity and gel filtration chromatography and sucrose gradient 
centrifugation. At around the same time, Parkos and colleagues also demonstrated that 
gp91phox co-purified with a 22kDa protein [27]. This work marked the discovery of the 
p22phox subunit of the cytochrome b558 heterodimer [28]. In his paper, Segal was able to 
demonstrate another phenomenon that has been borne out in countless further experiments in 
mouse and studies in humans, namely that both subunits were missing in patients in X-linked 
chronic granulomatous disease even though p22phox is transcribed from a separate, autosomal, 
locus. As it transpires, the proteins are only stable as a heterodimer and are rapidly degraded 
in the absence of their partner [29, 30] - in cases of autosomal recessive p22phox deficiency, 
gp91phox is also absent. As well as stabilising the expression of gp91phox, p22phox has an 
important role in facilitating the binding of the cytosolic components p67phox and p47phox to 
the cytochrome b558 heterodimer and allowing full activation of the oxidase [25]. This role is 
clearly demonstrated in a case of autosomal recessive chronic granulomatous disease caused 
by a point mutation in the proline rich C-terminus of p22phox. This mutation allows normal 
expression of the protein but recruitment of p67phox and p47phox to the membrane following 
activation was virtually abolished [31]. 
Characterisation and function of the cytoplasmic components of the phagocyte NADPH 
oxidase 
The discovery of cytochrome b558 represented years of incisive work on the basic 
biochemistry of phagocytes. This combined with shrewd clinical observation of CGD had 
delineated an entire system of anti-microbial defence. Nevertheless, the recognition that 
chronic granulomatous disease resulted from deficiency of an NADPH oxidase did not tell the 
whole story. The CYBB gene encoding gp91phox is situated on the X-chromosome but work 
by Borregaard and colleagues [32] demonstrated that some cases of CGD were autosomal 
recessive, a fact highlighted in one of the first multi-centre descriptions of a large cohort of 
CGD patients [33]. Moreover, patients with autosomal recessive CGD appeared to have a 
slightly less severe clinical course and normal levels of gp91phox [33]. Nevertheless, such 
patients had defects in electron transfer suggesting that proteins other than gp91phox were 
necessary to fully “activate” the process. Ultimately, these observations led to the identification 
of the p47phox and p67phox cytosolic subunits. The first hint of a cytosolic component to the 
process came from observations following PMA stimulation of neutrophils. PMA is known to 
be a potent stimulator of the phagocyte respiratory burst via protein kinase C and work in 
Segal’s laboratory showed that a cytosolic protein of 44-47kDa failed to become 
phosphorylated in certain cases of autosomal recessive CGD [34].  
Further characterisation of p47phox and the discovery of p67phox were aided by the 
development of cell-free systems in which the superoxide could be generated by extracts of 
neutrophil plasma membrane or specific granules mixed with cytosol. This technique allowed 
fractions of cytosol corresponding to different-sized proteins to be assayed for ability to 
augment NADPH oxidase activity. The principle of the cell-free assay depends on mixing 
neutrophil sub-cellular fractions with ionic amphiphiles such as arachidonic acid [35-37] or 
SDS [38] that stimulate the respiratory burst. Such assays showed that a mixture of crude 
membrane preparations and cytoplasmic extract were required to re-constitute oxidase activity. 
Interestingly, in cases of autosomal recessive CGD, the deficiency seemed to lie in the 
cytoplasmic component whereas in X-linked disease, the problem lay in the membrane 
fraction.   
Volpp et al [39] modified the cell-free technique based on the observation that the oxidase 
activity of cell free systems was augmented by the addition of GTP, which suggested that GTP-
binding proteins might be involved. They purified such proteins by GTP-agarose affinity 
chromatography and found that all of the super-oxide generating capacity of the cytosol resided 
in the GTP-bound fractions. Taking the active part of the cytosol, they raised anti-sera against 
the proteins within it and found that the antibodies they generated reacted with 2 proteins of 
approximately 47 and 67kDa. Crucially, either p47phox or p67phox were absent in some cases 
of autosomal recessive CGD, confirming the role of these proteins as integral cytosolic 
components of the NADPH oxidase complex. Another paper also utilising cell free systems, 
published in the same issue of Science, demonstrated very similar results [40]. Cell free systems 
also demonstrate that recombinant p67phox and p47phox could rescue the defects in p67phox 
and p47phox-deficient cytosol.     
Further work has established that both p67phox and p47phox are rich in motifs required for 
protein-protein interactions. p67phox has two SH3 domains, a TPR (tetratricopeptide repeat) 
domain and a PB1 domain which is C-terminal to the SH3 domains. p67phox interacts with 
Rac through the TPR domains and p40phox through the PB1 domain. p47phox also possesses 
two SH3 domains and a proline rich domain. It has a number of C-terminal serines and is 
heavily phosphorylated during neutrophil activation. We will see later how p47phox is a key 
organiser and provides a “Go” signal for the activation of the oxidase. Phosphorylation of 
p47phox results in the relief of an auto-inhibitory conformation and exposure of the two SH3 
domains to allow its interaction with p22phox. The C-terminus of p47phox also binds to the C-
terminal SH3 domain of p67phox, and thus p47phox phosphorylation is thought to play a major 
role in orchestrating assembly and subsequent activation of the oxidase. 
The discovery and characterisation of p47phox and p67phox were major milestones in the field 
but purified extracts of these proteins were not sufficient to re-constitute the “cytoplasmic” 
element of the oxidase in vitro. As mentioned above, it was known that GTP could augment 
oxidase activity in cell-free systems and that a GTP-bound factor “Sigma 1” was also necessary 
for NADPH oxidase activity [41]. In 1991, Segal’s lab showed, by sequencing “Sigma 1” that 
it was actually 2 proteins, the small G-protein p21-Rac1 and GDP-dissociation inhibition factor 
(GDI) [42]. Rac2 was then identified as a component of the neutrophil cytosol that could 
augment the respiratory burst using very similar techniques. Subsequent work has borne out 
the early suggestion that Rac2 is the predominant isoform in neutrophil while Rac1 seems more 
important in macrophages [43, 44].  
 
Cell free systems had a major impact on the field and thus allowed the description of the 
minimal components of the oxidase but they still did not tell the whole story. For instance, 
when p67phox is purified by gel filtration chromatography, it separates as part of a complex 
with a mass of 250kDa [45]. One part of this complex is p47phox but Segal's lab purified 
another part of the complex which turned out to be p40phox [46]. p40phox was, however, not 
required to reconstitute the oxidase in cell free systems [46]. Early work on p40phox offered 
opposing views of its role, with publications that found that it could have both activating and 
inhibitory effects on the oxidase [47-49]. Several lines of evidence have shown that this protein 
contributes substantially to the activation of the NADPH oxidase, albeit in a more context-
dependent manner than the other components.  In this regard, the two p40phox-mutant mouse 
models have shed light on this mercurial molecule. Mice that are fully deficient in p40phox 
(p40phox-/-) [50] or those that carry a point mutation in the PX domain (p40phox-/ phoxR105Q) 
have been characterised. Both mice show impaired clearance of Staphylococcus Aureus and 
this work has established that the PX domain of p40phox is important in binding phosphatidyl-
inositol 3-phosphate at the phagosome and consequently, facilitating oxidase activation. 
However, some differences in the phenotype of the two mice highlight the complex role of 
p40phox in NAPDH oxidase biology. For instance, the fully p40phox-deficient mouse exhibits 
defects in the response to soluble stimuli such as fMLP, whereas the (p40phox-/ phoxR105Q) 
mouse does not. In this setting, it is important to bear in mind that complete removal of p40phox 
also results in de-stabilisation of p67phox expression [50, 51] and an approximate 55% 
decrease in the abundance of this protein so it can be difficult to differentiate the direct effects 
of p40phox-deficiency from the indirect effect on p67phox expression. The in vivo importance 
of p40phox in humans, has however, been conclusively demonstrated by the identification of 
CGD patients with mutations in p40phox [52]. The current model of the cytosolic components 
of the phagocyte NADPH oxidase at rest is that they exist in a complex with 1:1:1 stoichiometry 
but that p47phox may also exist as a free monomer (reviewed in [53]). 
  
 
Current understanding of oxidase activation 
Armed with the information above, it is possible to build a picture of how the oxidase is 
activated when phagocytes encounter pathogens. Activation of the NADPH oxidase requires 
the translocation of the cytosolic components either to the plasma membrane (in the case of 
extracellular ROS) or to the phagosome (in the case of intracellular ROS). This spatial 
separation of the cytosolic and membrane components prevents the oxidase being activated at 
rest [54]. After phagocytosis of a particle and closure of the phagocytic vacuole, the oxidase 
system is activated. Targeting of the components of the oxidase to the phagosome is highly 
likely to be dependent on the accumulation of phosphoinositol phosphates at the phagosomal 
membrane [55]. In this context, it is significant that both p40phox and p47phox contain PX 
domains which can bind phosphoinositides. Therefore, when the oxidase is activated, the 
cytosolic components translocate as a heterotrimer to associate with the phagosome. This 
interaction is also dependent on the presence of the membrane bound components as it is 
disrupted in their absence [56]. Upon activation, p67phox interacts directly with the 
cytochrome b558 heterodimer and in combination with Rac (in the GTP bound form), it is 
sufficient to drive electron transport across the phagosome [53]. Rac translocates to the 
phagosome independently of p67phox and interacts both with p67phox and the cytochrome 
b558. Various models of the exact role of Rac1/2 have been proposed. It has been posited to 
act both as a scaffold that facilitates the interaction between p67phox and gp91phox and also 
as a direct participant in electron transfer [57]. The importance of p47phox seems to be as an 
adaptor molecule that forms a bridge between p22phox and p67phox as well as binding to the 
cytoplasmic elements in gp91phox. It therefore acts to stabilise the interaction between 
cytochrome b558 and p67phox. Indeed, in cell-free systems, micro-molar rather than nano-
molar concentrations of p67phox are required to induce electron transport if p47phox is not 
present [58, 59]. As well as stabilising the p67phox-Rac-cytochrome b558 interaction, there is 
also evidence that p47phox can interact with cytochrome b558 and modify its function directly 
- most likely through binding of p22phox. p47phox has two SH3 domains which face each 
other forming a groove that is filled by a polybasic C-terminal region [53, 60]. In the resting 
state then, the p47phox-SH3 domains interact with the C-terminal region of the non-
phosphorylated protein and keep it in an “auto-inhibited” state. Upon activation, this polybasic 
region is phosphorylated inducing a release from its auto-inhibitory role and allowing the SH3-
domain groove to contact the C-terminus of p22phox [61]. Thus, in summary, p67phox and 
Rac interact with gp91phox and maximise electron transfer while p47phox contacts p22phox 
and acts to “organise” the complex into a stable form for maximal activation [53, 54, 62].  
Recent work on control gp91phox/p22phox expression 
Recently, significant advances have been made in understanding the abundance of the 
gp91phox-p22phox heterodimer is controlled. It is clear that expression of cytochrome b558 
can be controlled at both the transcriptional and post-transcriptional level. gp91phox and 
p22phox biosynthesis appears to be a relatively inefficient process as described in a key study 
by DeLeo and colleagues [63]. Using pulse chase experiments, they found that gp91phox was 
made as a high mannose precursor and glycosylated to gp91phox within 4-8 hours of chase. 
Unassembled monomers are rapidly degraded by the proteasome. Specifically, only around 
30% of gp91phox translated from the CYBB gene product is present at 8h post-pulse chase. 
This rapid degradation of gp91phox is rescued by proteasome inhibitors.  They also showed 
that heme acquisition by gp91phox is an absolute requirement for heterodimer formation and 
that if this process is blocked with succinyl acetone, individual gp65 (the high mannose 
precursor of gp91phox) and p22phox monomers get degraded. The glycosylation of gp91phox, 
however, takes place after heterodimer formation. From this data, it follows that gp91phox and 
p22phox might interact with proteins in the ER that shorten or prolong its half-life and this is 
indeed the case. Recently, an important study by Noubade and colleagues identified Nrros 
(negative regulator of reactive oxygen species) as a protein that associates with gp91phox to 
facilitate its degradation [64]. Deficiency of Nrros in mice causes increased expression of the 
gp91phox-p22phox heterodimer with a concomitant increase in the magnitude of the reactive 
oxygen burst that has beneficial effects for clearance of bacterial infection but detrimental in 
that it leads to a more severe disease course of experimental allergic encephalomyelitis (EAE). 
There is precedence for the regulation of gp91phox expression by ER chaperones. For instance, 
the heat shock proteins, hsp70 and hsp90, play reciprocal roles in cytochrome b558 stability 
[65, 66]. Hsp90 stabilises gp91phox expression whereas hsp70 facilitates its degradation via 
the hsp70-regulated ubiquitin ligase, CHIP [66]. Recently, our laboratory described Eros 
(Essential for Reactive Oxygen Species), a novel transmembrane protein that has profound 
effects on the abundance of the cytochrome b558 heterodimer. Eros-deficient mice have almost 
absent levels of gp91phox and p22phox despite expressing normal levels of mRNA for these 
proteins. Consequently, they have a markedly impaired phagocyte respiratory burst and die 
very quickly following infection with Salmonella or Listeria [67]. Control of the phagocyte 
respiratory burst can also be achieved by varying the stability of the p22phox subunit. Yang 
and colleagues showed that the adaptor protein, Rubicon, better known for its ability to regulate 
autophagy, could interact specifically with p22phox [68]. Rubicon aided p22phox localisation 
to phagosomes and overexpression increased p22phox and gp91phox levels while Rubicon 
markedly decreased cytochrome b558 expression. The authors hypothesised that Rubicon 
might either prevent p22phox degradation of facilitate folding of the protein [68]. While the 
cytochrome b558 can be controlled by the rate of degradation of the protein, its expression is 
influenced at the level of messenger RNA too [69]. For instance, mouse neutrophils lacking 
the nuclear envelope protein lamin beta receptor (Lbr) have severely reduced gp91phox 
transcription, lower levels of gp91phox protein and a highly impaired phagocyte respiratory 
burst.  Subsequent studies of Lbr also highlighted another important feature of cytochrome 
b558 biology, which is that the components localise to lipid rafts during activation. The lamin 
beta receptor has a role in cholesterol biosynthesis and interestingly, restoration of only the 
sterol reductase domain of the protein to Lbr-deficient neutrophils was able to partially restore 
the respiratory burst [70]. These results indicated that the lamin beta receptor may act in part 
by providing sufficient cholesterol for membrane lipid raft formation. 
These studies illustrate how it might make sense to regulate gp91phox at the level of protein 
expression so that it can be up-regulated in the setting of infection but tightly controlled to 
prevent excessive ROS driving auto-inflammatory processes. 
Chronic granulomatous disease and the role of ROS in regulating inflammation. 
As stated previously, the importance of the phagocyte NADPH oxidase is underlined by 
chronic granulomatous disease - deficiency of one of the subunits. Several cohorts have now 
been analysed. In Europe [71-74], the USA [75] and Japan [76], X-linked CGD is the 
predominant form accounting for around 60% of cases. Of those that remain, around 30% are 
the result of p47phox deficiency and 10% are p67phox or p22phox deficiency. In cohorts where 
consanguinous marriage is more prevalent, for instance, in the Turkish [77] or Iranian [78] 
cohorts, autosomal recessive CGD is the dominant form of the disease. 
XR-CGD patients traditionally have been thought to have a more severe disease course than 
patients with the AR form of the disease, presumably because they completely lack all oxidase 
activity. Indeed, the residual oxidase activity of neutrophils is predictive of disease severity 
and modest production of ROS seems to confer a greater likelihood of long-term survival.  
Reactive oxygen species as regulators of immunity 
An emerging theme of the last few years has been the role of reactive oxygen species not just 
as anti-microbial agents but as regulators of the immune system. ROS can have profound 
influences on redox sensitive cellular pathways. This function in immuno-regulation is not 
surprising as auto-inflammatory complications, particularly inflammatory bowel disease, have 
been recognised as a feature of CGD even from the initial characterisation of the syndrome.  
There are myriad ways in which reactive oxygen species might regulate immunity but it is 
thought that the bulk of the effect can be ascribed to the actions of hydrogen peroxide (reviewed 
in [79]. The superoxide ion has a relatively short half-life but it is readily degraded to hydrogen 
peroxide, which can pass freely through cell membranes. If produced at the cell surface, it can 
therefore have both intracellular and intercellular effects. The intracellular targets of reactive 
oxygen species are generally cysteines on proteins and the proven targets of H202 include major 
regulators of transcription accounting for their profound effects. These targets include both 
protein tyrosine kinases and protein tyrosine phosphatases. Several publications have 
highlighted how reactive oxygen species may influence multiple pathways in mammalian 
immunity and there is evidence for significant effects on both and adaptive immunity. The 
body of work on innate immunity, in particular, indicates that reactive oxygen species can 
regulate a diverse array of key cellular processes including autophagy, inflammasome 
formation and type 1 interferon signalling. [80-83]. Concomitantly, abnormalities in the 
generation of reactive oxygen species are associated with a variety of auto-inflammatory 
manifestations. Some specific examples of immune-regulation by the NADPH oxidase and 
how this may impact on self-tolerance are discussed below.  
ROS regulation of innate immunity 
ROS and Type 1 Interferon Signalling 
The work of Holmdahl and colleagues on p47phox as a regulator of innate immunity provides 
some key insights into the regulatory role played by ROS in the immune system. This group 
has investigated p47phox-deficiency as a driver of inflammatory arthritis in rat and mouse with 
complementary studies in human cells ex vivo. They identified Ncf1 (p47phox) as a 
susceptibility locus in pristine induced arthritis by examining a resistant and susceptible rat 
strain and making a series of genetically segregated F2 crosses. This work showed that the 
strongest association with susceptibility or resistance was a quantitative trait locus (QTL) on 
rat chromosome 12. Surprisingly, the causative mutation was a coding variant in p47phox that 
led to an impaired phagocyte respiratory burst [84]. This was slightly unexpected in that one 
might expect that excessive reactive oxygen species production with concomitant tissue 
damage might be a more likely route to autoimmunity. 
The same group then investigated the mechanisms by which a lack of p47phox might influence 
autoimmunity and focused first on the transcriptional effects of Ncf1 (p47phox)-deficiency in 
mice and chronic granulomatous disease in children. Using myeloid-derived cells, they showed 
that a lack of ROS was associated with a large increase in the transcription of genes that are 
regulated by type 1 interferon. Of note, many of the up-regulated genes, were downstream of 
STAT1, a transcription factor that was up-regulated both in cells of patients with CGD and 
Ncf1-deficient mice. This finding is of particular interest because genome wide association 
studies (GWAS) have shown that NCF2, which encodes the cytoplasmic p67phox component 
of the phagocyte NADPH oxidase is a susceptibility locus both in childhood and adult SLE 
[80-83, 85, 86]. Moreover, SLE is known to be characterised by overexpression of the same 
type one interferon pathway transcripts that are so highly expressed in the CGD patients and 
p47phox-deficient mice.  The finding that NCF2 is a susceptibility locus has been validated in 
multiple cohorts and some elegant functional work has elucidated the probable role of NCF2 
polymorphisms in disease. Intriguingly, individuals with the risk allele have an impaired 
phagocyte respiratory burst via reduced Fcγ receptor-elicited NADPH oxidase activity. This is 
consistent with data suggesting that gp91phox deficiency pre-disposes to lupus in both mouse 
and man [87, 88]. Aside from SLE and IBD [89, 90], genetic variation in p40phox (NCF4) has 
also been implicated in atopic dermatitis [91]. A summary of the involvement of the phagocyte 
NADPH oxidase in autoimmune diseases can be found in Table 1.  
ROS and autophagy 
Autophagy is responsible for degradation and recycling of intracellular proteins and damaged 
organelles, maintaining the normal cellular function. It is now also clear that autophagy can be 
used as a form of host defence, the machinery for engulfment and degradation of host proteins 
is well suited to disposing of microbes. One of the first publications demonstrating that 
antibacterial autophagy was regulated by ROS was published by Huang and colleagues [92]. 
This work showed that Nox2 is required to activate anti-bacterial autophagy because it is 
necessary for LC3 recruitment to phagosomes. Antibacterial autophagy in human epithelial 
cells was also dependent on ROS generation. Epithelial cells do not express the phagocyte 
NADPH oxidase so the ROS in this case must come from some other source and therefore this 
paper makes the important point that the regulation of autophagy by ROS is a general principle 
not restricted to phagocytes [92].  
Not only are ROS required for autophagy but also for LC3-asscociated phagocytosis, a process 
distinct from autophagy that utilises some of the same molecular machinery [93, 94]. This 
process results in the lipidation of LC3 on a phagosomal rather than autophagosomal membrane 
and while dependent on many autophagy proteins, it occurs independently of the pre-initiation complex. 
A recent detailed description of the process by which LC3-associated phagocytosis proceeds 
showed that Rubicon is recruited to phagosomes; this activates class III PI3 kinases which 
generates PtdIns(3)P. This process, in turn, allows the stabilisation of components of the 
phagocyte NADPH oxidase at the phagosome. The presence of Nox2-derived ROS is essential 
for the recruitment of LC3 to the so-called LAPosome and for this structure to fuse with 
lysosomes [95]. The non-redundant role of the phagocyte NADPH oxidase in this process is 
especially interesting in light of a recent report from the same group that mice that lack 
component of LAP, though not canonical autophagy, develop an SLE-like syndrome [96].  
While ROS can clearly regulate autophagy, it is important to bear in mind that this is a two- 
way street, given that autophagy components such as Rubicon also control abundance of 
cytochrome b558 [68].   
ROS and the inflammasome 
In addition to regulating type 1 interferon signaling, autophagy and LC3-associated 
phagocytosis, there is now good evidence that ROS can regulate activation of the 
inflammasome, the cytosolic multiprotein scaffold that generates IL-1 and IL-18 through the 
actiavtion of caspase 1. Intriguingly, this regulation seems to take place via autophagy. For 
instance, De Luca et al [97] showed, consistent with the work described above, that LC3 failed 
to be recruited to phagosomes of macrophages from p47phox-/- mice or gp91phox-/- human 
monocytes and that this led to increased IL-1 production with a concomitant increase in 
neutrophil recruitment and an exuberant Th17 response. Importantly, treatment with anakinra 
(anti-IL-1R antibody) improved colitis both in the murine model and the inflammatory bowel 
disease in patients with CGD. This paper followed an initial report  showing that monocytes 
from patients deficient in gp91phox, p22phox or p47phox all exhibited elevated levels of IL-
1 and caspase 1 [98].  
Dys-regulated inflammasome activation secondary to ROS-deficiency has also been explored 
in a mouse model of ANCA-driven crescentic glomerulonephritis. In this model, vasculitis can 
be transferred to mice by passive transfer of anti-myeloperoxidase (MPO) antibodies to 
recipient mice. The ANCA-driven glomerulonephritis is much more severe if the host mouse 
has been irradiated and then re-constituted with either gp91phox-/- or p47phox-/- bone marrow. 
Thus, the presence of ROS-deficient haematopoietic cells exacerbates antibody-driven 
glomerulonephritis and this was associated with increased IL-1 secretion in gp91phox-/- and 
p47phox-/- chimaeras. The enhanced IL-1 secretion could be abrogated by caspase1 blockade 
and indeed, chimaeras that were both gp91phox and caspase1-deficient did not show more 
severe glomerulonephritis than control mice [99].    
Interestingly, there is evidence that there is reciprocal interplay between ROS and 
inflammasome signalling in that activation of the inflammasome via certain specific pathways, 
such as ATP-driven NLRP3 activation, can lead to rapid ROS induction[100, 101].  
ROS regulation of adaptive immunity 
It is clear, therefore that reactive oxygen species influence many fundamental processes in the 
innate immune system. There is also good evidence that reactive oxygen species can also 
modulate the activity of cells of the adaptive immune system. These effects can be indirect 
because of the influence of ROS on innate immune signaling and antigen presentation and by 
paracrine diffusion of hydrogen peroxide from antigen presenting cells. However, there is also 
evidence that lymphocytes can express components of the phagocyte NADPH oxidase. 
The evidence for indirect effects on T cells mediated via APCs is covered in two excellent 
reviews of the topic [51, 79]. Three key results, however, emphasise a role for intercellular 
ROS, however. The first is that wild-type T cells, which cannot transfer arthritis, become 
arthritogenic when the number of thiol groups on the surface is artificially increased [102] – 
this emphasises the notion that ROS from other cells diffusing to the T cell surface can 
influence its phenotype irrespective of any ROS generation by the T cell itself. The second 
important finding is that a defect in macrophages lacking cytochrome p47phox can prime type 
II collagen-reactive T cells, which can then cause disease [103]. Finally, in the Ncf1-deficient 
collagen induced arthritis model, in which the arthritis is largely T cell driven, the phenotype 
can be rescued if Ncf1 expression is restored to the macrophages only [104].     
While the actions of intercellular ROS are undoubtedly important, it has long been known that 
T cells express measurable levels of the cytochrome b558 heterodimer. Stimulation through 
the T cell receptor drives superoxide production that is dependent on both on the NADPH 
oxidase and Fas [105] but it is notable that other, non NADPH-oxidase dependent ROS are 
produced following TCR stimulation, possibly from mitochondria. Nox2-deficiency certainly 
has a functional effect on T cells in that they are skewed towards Th1 cytokine production [50]. 
As mentioned above, ROS might influence T cell activation through multiple pathways but the 
modification of kinases and phosphatases involved in T cell signaling seems the most likely 
route.    
B cells can also express components of the phagocyte NADPH oxidase, although, as is the case 
for T cells, the expression of these is lower than that found in neutrophils and macrophages. B 
cells deficient in NADPH oxidase components do seem to have altered B cell receptor signaling 
[106] and patients who have chronic granulomatous disease have abnormal antibody responses, 
though of course this latter finding might be due to defects in the innate immune system [107].  
Conclusions 
The phagocyte respiratory burst is essential for host defence and the study of chronic 
granulomatous disease has not only emphasised this point but has illuminated the complex 
biochemistry of this pathway. Recent work on chaperone proteins that control levels of 
gp91phox and p22phox demonstrate that we still have much to learn about the respiratory burst. 
A particularly exciting development in the last few years has been the recognition that the 
phagocyte NADPH oxidase regulates not only major pathways in immunity such as type 1 
interferon signaling and the inflammasome but basic and ancient cellular processes such as 
autophagy. Indeed, the finding that genetic variation in NADPH oxidase genes are risk factors 
in human auto- inflammatory diseases, coupled with abundant evidence from animal studies, 
emphasises the need to understand the process more fully in order to optimise therapy for such 
illnesses. Finally, although this review has not dealt with the literature in detail, there is strong 
evidence that the phagocyte NADPH oxidase influences both cardiovascular disease and 
melanoma metastasis [108-110]. There is still much work to be done in these areas but the 
respiratory burst is clearly a fertile area for research that will ultimately lead to improvements 
in human health. 
 
  
Table 1 – The involvement of the phagocyte NADPH oxidase in 
autoimmunity 
Subunit Associated autoimmune 
disease 
Reference 
gp91phox (CYBB) S.L.E. (mouse and human)  
I.B.D 
 
87, 88 
71-78 
p47phox (NCF1) Arthritis (rat and mouse) Reviewed in 79 
p67phox (NCF2) S.L.E (mouse and human) 80,81,82,83,85,86 
p40phox (NCF4) I.B.D., atopic dermatitis 
(human GWAS studies) 
89, 90, 91 
 
 
Figure 1 – A schematic diagram of the NADPH oxidase and the 
factors that regulate abundance of gp91phox  
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